Public support for resident doctors' strikes collapses ahead of fresh industrial action
Previously strong approval by voters for strikes by junior doctors – as resident doctors were known until last year – has halved from 52% a year ago to just 26%.
The fall may be linked to the fact that resident doctors in England got a 22% salary uplift from the Labour government soon after it took power in July 2024 but now want another 29% – spread over several years – to restore the real-terms value of their pay to what it was in 2008.
The new polling by Ipsos, seen exclusively with the Guardian, will increase pressure on Wes Streeting, the health secretary, to reach a compromise with the British Medical Association (BMA) before a planned five-day walkout by tens of thousands of resident doctors on 25 July.
Two in five (41%) of British adults oppose the strikes and 24% are neutral. Slightly more Labour voters (35%) back the doctors' action than oppose it (32%), with 24% neutral.
'If resident doctors do take strike action this summer, it will be the first time for some years that they go on industrial action without broad-based support from the public, including from Labour voters,' said Gideon Skinner, Ipsos's senior director of UK politics.
The survey findings also contain bad news for Streeting and Keir Starmer, the prime minister. More than two in five people (43%) think the government is doing a bad job at negotiating with the trade unions. An increase of 7% since Ipsos asked that question last October and almost twice as many as those who thought that (23%) last August.
'Although there is increasing criticism of the way the Labour government is handling negotiations with unions, Labour is not yet receiving the negative ratings that Rishi Sunak's government saw [when 60% disapproved of its handling of union pay claims], while public perceptions towards the wider picture of public finances are also likely to be playing a part,' Skinner added.
A separate new poll by YouGov reported by the Times found that 36% of voters support the doctors' strikes while 49% are opposed.
When the Guardian interviewed the new BMA leader, Dr Tom Dolphin, last Wednesday, before Ipsos's findings emerged, he acknowledged that public support had fallen and that voters 'will wonder' why more strikes are looming.
'Doctors have been hugely grateful to the public for their support the whole way through this dispute but I completely understand how people might be feeling now, although there are plenty who do still support us.
'No one likes to have their lives and routines disrupted and particularly when it comes to health and wellbeing, we know people can feel worried.
'The public will remember what the last round of strikes meant for them and their families and now they've seen resident doctors getting a pay rise, people will wonder why it's happening all over again. The reason why is that the [22%] pay rise was only part of the journey to restoring the value of our pay that we're campaigning for.'
But people would understand why resident doctors were pursuing such a large increase and said media coverage of it was encouraging 'jealousy', he added.
Asked how seeking a 29% pay rise soon after getting a 22% uplift looks to the public, Dolphin said: 'I think the public should expect their doctors to be valued properly. I think if you explain to people, when we do explain to people in individual conversations about: 'What would you do if you had had a 30% pay cut? What would you feel about it? How would you react?', people do understand [the BMA seeking] that [further large rise].
'Fundamentally, when you talk to people about the unfairness of that and that loss of value, people get it. They understand and they would do the same if they could to restore that value.'
Another recent poll, by the Good Growth Foundation, found that even fewer voters endorse the resident doctors walkouts – 23% – than the 26% identified by Ipsos.
Ipsos interviewed a representative online sample of 1,023 adults aged 18 to 75 across Great Britain on Wednesday and Thursday, just after news of the five-day strike emerged.
Wes Streeting said: 'Public support for strikes has collapsed, following the 28.9% pay rise resident doctors have received thanks to this government. Patients are begging resident doctors not to walk out on them.
'Instead of rushing down this unreasonable path, the BMA need to pause and think about the real risk of people losing trust in doctors and the damage that would do to our NHS and the entire medical profession.
'My plea continues to be for the BMA to listen to the public on this, and the majority of resident doctors who did not vote for these strikes. Call off these unnecessary and unfair strikes, work with the government to improve working conditions for resident doctors, and let's keep rebuilding our NHS.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
North Wales Chronicle
23 minutes ago
- North Wales Chronicle
Child in Liverpool dies after contracting measles
According to The Sunday Times newspaper, the child was ill with measles and other health problems and was receiving treatment at the Alder Hey Children's Hospital. A statement from the Alder Hey Children's NHS Foundation Trust said: 'To respect patient confidentiality, we can't comment on individual cases. 'We are concerned about the increasing number of children and young people who are contracting measles. Measles is a highly contagious viral illness which can cause children to be seriously unwell, requiring hospital treatment, and in rare cases, death. 'The number of children being treated at Alder Hey for effects and complications of measles is increasing (we have treated 17 since June). 'We treat children with a range of conditions and illnesses in our hospital, including those with compromised immunity due to other health issues, making them more susceptible to infections, including measles. 'We can prevent people, including children, from contracting measles through vaccination. Please protect yourself and vulnerable children and young people by ensuring you are fully vaccinated.' The child is believed to be the second to succumb to an acute measles infection in Britain this decade. It comes after a Royal College of Paediatrics and Child Health (RCPCH) report released earlier this month determined uptake of vaccines in the UK has stalled over the last decade and is, in many cases, declining. None of the routine childhood vaccinations have met the target for 95% coverage since 2021, meaning youngsters are at risk of catching illnesses such as measles, meningitis and whooping cough. The report said while some families are hesitant to vaccinate due to fears about the jabs, many face issues that could be resolved with more support, including difficulties booking and attending appointments and a lack of continuity of NHS care, with many parents seeing a different GP or clinician at each visit.
The Independent
26 minutes ago
- The Independent
Child in Liverpool dies after contracting measles
A child in Liverpool has died after contracting measles, it has been reported. According to The Sunday Times newspaper, the child was ill with measles and other health problems and was receiving treatment at the Alder Hey Childre n's Hospital. A statement from the Alder Hey Children's NHS Foundation Trust said: 'To respect patient confidentiality, we can't comment on individual cases. 'We are concerned about the increasing number of children and young people who are contracting measles. Measles is a highly contagious viral illness which can cause children to be seriously unwell, requiring hospital treatment, and in rare cases, death. 'The number of children being treated at Alder Hey for effects and complications of measles is increasing (we have treated 17 since June). 'We treat children with a range of conditions and illnesses in our hospital, including those with compromised immunity due to other health issues, making them more susceptible to infections, including measles. 'We can prevent people, including children, from contracting measles through vaccination. Please protect yourself and vulnerable children and young people by ensuring you are fully vaccinated.' The child is believed to be the second to succumb to an acute measles infection in Britain this decade. It comes after a Royal College of Paediatrics and Child Health (RCPCH) report released earlier this month determined uptake of vaccines in the UK has stalled over the last decade and is, in many cases, declining. None of the routine childhood vaccinations have met the target for 95% coverage since 2021, meaning youngsters are at risk of catching illnesses such as measles, meningitis and whooping cough. The report said while some families are hesitant to vaccinate due to fears about the jabs, many face issues that could be resolved with more support, including difficulties booking and attending appointments and a lack of continuity of NHS care, with many parents seeing a different GP or clinician at each visit.
The Guardian
26 minutes ago
- The Guardian
Microdosing: how ‘off-label' use of weight loss jabs is spreading from US to UK
A slim woman standing in a kitchen injects herself in the abdomen. Another jogs. A third kneels on a yoga mat drinking water. The shots are intercut with a doctor telling the viewer: 'Usually it's for people who don't actually have that much to lose – it's a bit of a gentler way to get to your target weight.' The promotional video is from a private clinic in Leicester offering 'microdosing', the latest trend in the weight loss jab revolution. The experimental approach involves taking less than the recommended dose of a GLP-1 medication such as Ozempic, Mounjaro or Wegovy in the hope of curbing hunger pangs just enough to sustain weight loss. The use is 'off-label' – doctors can prescribe a medicine in a different way than stipulated in its licence if they follow official guidelines – as there is little scientific research to show that it works and is safe. Nevertheless, the practice is becoming increasingly popular with people who want to shift a few pounds but fall outside the drugs' target market of patients who are obese, overweight or diabetic. Promoted by health influencers on social media, microdosing first became popular in the US, where the costs of the drugs are much higher – Novo Nordisk's Wegovy has a list price of $1,349 (£997) a month while Eli Lilly's Mounjaro is $1,080. Now the trend is catching on in the UK. The Healand clinic in Leicester has been offering a microdose treatment for about a year, priced from £175 a month including support. Healand has 750 patients on it so far, who start on a fifth of the normal dose. Dr Omar Babar, the reassuring figure speaking in its promotional video, tells the Guardian that microdosing benefits perimenopausal women who, because of hormonal changes, gain weight and struggle with fatigue and brain fog. His clinic also attracts men in their 30s as well as older men up to age 70. 'The idea is not to feel so suppressed, not to feel like you can't eat any more,' Babar says. 'The idea is that you just get a bit more gentle suppression of cravings. A lot of people use it to help curb their alcohol consumption as well.' His clients typically lose between 5kg (11lb) and 10kg. Nearly all work out several times a week and a lot are in 'high-functioning jobs' and want 'a bit more control over their health', Babar says. The Aestha clinic, in central London, also offers the treatment as a way to lose a little weight or slim down more gradually – its website describes its 'refined approach to GLP-1 therapy, utilising about a tenth of standard dosing protocols' – as do pharmacies in Hertfordshire and Kent. The trend has been gaining traction since last October, when Dr Andrew Huberman, a neuroscientist at Stanford University school of medicine and podcaster, posted an interview on X with the 'performance medicine expert' Dr Craig Koniver, who hailed it as a 'gamechanger'. Koniver says it helps to avoid the loss of lean muscle mass through more gradual weight loss and does away with 'Ozempic face' – a gaunt look that rapid weight loss sometimes causes. Microdosing as a term originally referred to using tiny quantities of psychedelics to treat mental health problems. In the case of GLP-1 jabs, it involves counting clicks on the pre-filled pen to deliver less than the recommended amount. Users hope to limit side-effects, such as vomiting, cut the cost and experience other health benefits, despite the low dose. Over the past 10 weeks, Jade, a 32-year-old from London, has been injecting 1mg of Mounjaro every Monday – less than half the standard starting dose of 2.5mg – to reduce inflammation and pain caused by endometriosis, while losing some weight. 'The inflammation is completely gone,' she says. 'I'm not in any pain, whereas in severe pain I'm crying, lying on the floor in absolute agony. I've not had any side-effects from Mounjaro because I'm using such a small dose.' She is pleased to have also lost just over a stone (6.4kg). 'It took away a bit of the food noise. I wasn't necessarily thinking about food like I normally do.' Jade spends £13 a week on Mounjaro – 'which is nothing, you spend more in Marks & Spencer on lunch'. Demand for what have been hailed as 'miracle drugs' has spawned a wave of online weight management companies that have registered with the Care Quality Commission to sell the medications in the UK. Those companies include Voy, Manual, Juniper, Numan and CheqUp. In May CheqUp struck a partnership with Weight Watchers as part of the brand's shift away from dieting after filing for bankruptcy in the US earlier in the month. However, as of this week online pharmacies are no longer allowed to run adverts for weight-loss injections, after the advertising watchdog cracked down on what has been described as a 'wild west' culture of online selling: in the UK prescription only-medications cannot be promoted to the public. Use of the drugs has soared in recent months: CheqUp estimates 1.25 million people take GLP-1s in the UK; the health data firm IQVIA puts the number at 1.5 million. The vast majority buy them privately because the NHS has restricted treatment to the most obese patients. Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion James Hunt, deputy chief executive of CheqUp, talks of a revolution. 'We have never had a category of medication which has tempted 1.25 million people to say, actually, I'm going to forgo the NHS, I'm going to look after myself and self-medicate.' He estimates that 80% of GLP-1 users are women and a fifth are men, even though the obesity split in the population is 50-50. Wegovy and Mounjaro are available to buy through private prescription in the UK at all the big high street pharmacy chains and online pharmacies. Prices for a month's supply for Mounjaro range from £129 to £249, depending on dosage. Prices for Wegovy range from £119 to £299. To be eligible, people must have a BMI of 30 or over, or 27 to 29 with at least one other weight-related health problem, such as diabetes. They need to complete an online form with questions about their weight and medical history. New rules from the General Pharmaceutical Council mean people should also have an in-person or video consultation, or supporting information from their GP or medical records, to be approved. The drugs work by mimicking the gut hormone GLP-1, which regulates blood sugar levels and appetite. Research suggests there are benefits beyond weight loss. A study published in January found the drugs reduced the risk of 42 diseases, including heart disease, cancer, clotting disorders, Alzheimer's, chronic kidney disease, addiction and a range of psychiatric conditions. However, hundreds of people taking the medications have reported pancreas-linked problems, prompting health officials to launch fresh research into the drugs' side-effects. While CheqUp, Voy, Juniper and Numan stick to guidelines from Britain's Medicines and Healthcare products Regulatory Agency and do not promote GLP-1 microdosing, many health influencers on social media advocate it as 'personalised dosing', targeting perimenopausal women aged 35-plus in particular. Some athletes also say they microdose to help with weight loss and performance. The US health influencer Dr Tyna Moore promotes microdosing not just for weight loss but to help with conditions such as high blood pressure, autoimmune diseases and brain fog. Her $2,300 online course, GLP-1s Done Right University, includes advice on microdosing, but she advises against self-dosing and urges users to find a 'longevity doc' who prioritises lifestyle. In the UK, Graham Phillips describes himself as 'the pharmacist who gave up drugs' and runs two pharmacies, in Letchworth and Broadstairs, that offer a 'prolongevity' programme that promotes weight loss through natural means, such as cutting out ultra-processed foods and monitoring blood glucose levels. Some of his clients are given the 2.5mg starting dose of Mounjaro less frequently than the standard weekly dosage. 'You may not need one at all, but without doubt, some people, even if they're following all our recommendations, they really struggle with … appetite control and food addiction,'Phillips says. 'Using a microdose, you can often switch that off.' Many doctors and health experts are wary of the practice, however, saying it can lead to unpredictable outcomes. The Lancet said in an article in February: 'The practice of microdosing drugs is not new, but there is no evidence that it works for obesity.' Ann Marie Defnet, a bariatric surgeon at Northwell Health, New York state's largest healthcare provider, says in its health publication the Well: 'Clinical trials are where we figure out whether a treatment is both effective and safe. And none of the big GLP-1 trials studied anything like 'microdosing'. So right away, if you're going off-label, you're stepping into the unknown.'
